Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab and Iberdomide in Relapsed/Refractory Multiple Myeloma
NCT06465316Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iberdomide in multiple myeloma (MM), sponsored by National Cancer Institute. Primary endpoints: Recommended Phase 2 Dose at 28 days and Maximum Tolerated Dose at 28 days. Started Dec 2024; status: recruiting.
02
Drugs
iberdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06465316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06465316.